Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Sponsor: Samsung Medical Center
This PHASE1/PHASE2 trial investigates Advanced Gastric Adenocarcinoma and is currently completed. Samsung Medical Center leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Mar 2022 — Jul 2022 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
-
Mar 2019 — Jan 2020 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .